Phaseline

Companies › Leal Therapeutics

Leal Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Psychiatry, Neurology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LTX-001–Phase 1SchizophreniaMar 2027
LTX-002
Antisense oligonucleotide (ASO) targeting SPTLC1 mRNA
SPTLC1Phase 1Amyotrophic Lateral SclerosisJun 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07734493LTX-001Phase 1SchizophreniaPsychiatryMar 2027
NCT07660614LTX-002Phase 1Amyotrophic Lateral SclerosisNeurologyJun 2031

Targets

SPTLC1 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.